Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
:INSM
INSM Analyst Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
INSM Stock 12 Month Forecast
Average Price Target
$114.50
▲(2.59% Upside)
| Highest Price Target$135.00 | Average Price Target$114.50 | Lowest Price Target$101.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$111
Hold
-0.55%
Downside
Reiterated
08/01/25
TD Cowen
$114→$135
Buy
20.96%
Upside
Reiterated
07/22/25
Wells Fargo
$119→$130
Buy
16.48%
Upside
Reiterated
07/22/25
Insmed's Promising Outlook: Buy Rating Backed by Brenso Launch and Market PotentialWe also identified preclinical studies evaluating NSP inhibition or CTSC modulation in models that mimic CRSsNP features or share similar inflammatory profiles. These data suggest that targeting NSPs may help reduce neutrophilic inflammation and overall disease burden, reinforcing the biological plausibility of the approach. We also note the unknowns. We were unable to identify preclinical or clinical evidence directly linking NSP reduction to symptom relief in CRSsNP patients, and our KOL checks confirmed that such data remains limited. Additionally, given the heterogeneity of CRSsNP, INSM's eosinophil cutoff in the trial, and the use of a PRO-based primary endpoint, we expect some level of investor skepticism around the PoS of this program. Our DCF-based PT goes to $130 from $119.
J.P. Morgan
$111
Buy
-0.55%
Downside
Reiterated
07/17/25
Morgan Stanley
$102→$108
Buy
-3.23%
Downside
Reiterated
07/17/25
RBC Capital
$106→$108
Buy
-3.23%
Downside
Reiterated
07/07/25
Mizuho Securities
$110
Buy
-1.44%
Downside
Reiterated
06/17/25
Leerink Partners
$100→$115
Buy
3.04%
Upside
Reiterated
06/11/25
Truist Financial
$108
Buy
-3.23%
Downside
Reiterated
06/11/25
H.C. Wainwright
$90→$120
Buy
7.52%
Upside
Reiterated
06/11/25
Evercore ISI
$90→$110
Buy
-1.44%
Downside
Reiterated
06/11/25
Bank of America Securities
$94→$109
Buy
-2.34%
Downside
Reiterated
06/10/25
Stifel Nicolaus
$92→$110
Buy
-1.44%
Downside
Reiterated
06/10/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$111
Hold
-0.55%
Downside
Reiterated
08/01/25
TD Cowen
$114→$135
Buy
20.96%
Upside
Reiterated
07/22/25
Wells Fargo
$119→$130
Buy
16.48%
Upside
Reiterated
07/22/25
Insmed's Promising Outlook: Buy Rating Backed by Brenso Launch and Market PotentialWe also identified preclinical studies evaluating NSP inhibition or CTSC modulation in models that mimic CRSsNP features or share similar inflammatory profiles. These data suggest that targeting NSPs may help reduce neutrophilic inflammation and overall disease burden, reinforcing the biological plausibility of the approach. We also note the unknowns. We were unable to identify preclinical or clinical evidence directly linking NSP reduction to symptom relief in CRSsNP patients, and our KOL checks confirmed that such data remains limited. Additionally, given the heterogeneity of CRSsNP, INSM's eosinophil cutoff in the trial, and the use of a PRO-based primary endpoint, we expect some level of investor skepticism around the PoS of this program. Our DCF-based PT goes to $130 from $119.
J.P. Morgan
$111
Buy
-0.55%
Downside
Reiterated
07/17/25
Morgan Stanley
$102→$108
Buy
-3.23%
Downside
Reiterated
07/17/25
RBC Capital
$106→$108
Buy
-3.23%
Downside
Reiterated
07/07/25
Mizuho Securities
$110
Buy
-1.44%
Downside
Reiterated
06/17/25
Leerink Partners
$100→$115
Buy
3.04%
Upside
Reiterated
06/11/25
Truist Financial
$108
Buy
-3.23%
Downside
Reiterated
06/11/25
H.C. Wainwright
$90→$120
Buy
7.52%
Upside
Reiterated
06/11/25
Evercore ISI
$90→$110
Buy
-1.44%
Downside
Reiterated
06/11/25
Bank of America Securities
$94→$109
Buy
-2.34%
Downside
Reiterated
06/10/25
Stifel Nicolaus
$92→$110
Buy
-1.44%
Downside
Reiterated
06/10/25
Best Analysts Covering Insmed
1 Month
xxx
Success Rate
9/15 ratings generated profit
Average Return
+9.17%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +9.17% per trade.
3 Months
xxx
Success Rate
17/21 ratings generated profit
Average Return
+35.52%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +35.52% per trade.
1 Year
Success Rate
14/14 ratings generated profit
Average Return
+97.76%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +97.76% per trade.
2 Years
xxx
Success Rate
21/21 ratings generated profit
Average Return
+186.30%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +186.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
INSM Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
1
6
6
5
0
Buy
42
32
36
33
22
Hold
6
6
10
7
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
49
44
52
45
28
Each month's total comprises the sum of three months' worth of ratings.
INSM Financial Forecast
INSM Stock Forecast FAQ
What is INSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is 114.50.
What is INSM’s upside potential, based on the analysts’ average price target?
Insmed has 2.59% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INSM a Buy, Sell or Hold?
Insmed has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
What is Insmed’s price target?
The average price target for Insmed is 114.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $135.00 ,the lowest forecast is $101.00. The average price target represents 2.59% Increase from the current price of $111.61.
The highest analyst price target is $135.00 ,the lowest forecast is $101.00. The average price target represents 2.59% Increase from the current price of $111.61.
What do analysts say about Insmed?
Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
How can I buy shares of INSM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.